Search
Brobactam
go.drugbank.com/drugs/DB20131ExperimentalBrobactam has a monoisotopic molecular weight of 278.96 Da.
Synonyms: Sulbactam related compound d, Sulbactam sodium impurity dFandosentan
go.drugbank.com/drugs/DB20193ExperimentalFandosentan has a monoisotopic molecular weight of 517.08 Da.
Talorasib
go.drugbank.com/drugs/DB21686ExperimentalTalorasib has a monoisotopic molecular weight of 604.24 Da.
JSM 6427
go.drugbank.com/drugs/DB06139InvestigationalJSM 6427 is the first small molecule alpha5beta1 integrin receptor antagonist of its kind to be developed. It has been biologically validated for therapeutic use in the prevention and treatment of wet AMD, the leading cause of blindness ...
WU-CART-007
go.drugbank.com/drugs/DB18617InvestigationalWU-CART-007 consists of allogeneic, fratricide-resistant genetically modified T cells transduced with a 2nd generation 4-1BB-CD3z chimeric antigen receptor targeting human CD7.
Danicamtiv
go.drugbank.com/drugs/DB18962InvestigationalDanicamtiv is under investigation in clinical trial NCT04572893 (Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants or Other Causalities).
Tebapivat
go.drugbank.com/drugs/DB19338InvestigationalTebapivat is under investigation in clinical trial NCT05490446 (A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-risk Myelodysplastic Syndromes (LR-MDS)).
Synonyms: 6-[(6-aminopyridin-2-yl)methyl]-4-methyl-2-[(1H-pyrazol-3-yl)methyl]-4,6-dihydro-5H-[1,3]thiazolo[5',4':4,5]pyrrolo[2,3-d]pyridazin-5-oneHuman interferon beta
go.drugbank.com/drugs/DB14999ApprovedInvestigational[L12078] Interferon-beta has been used in the past in clinical studies with other coronaviruses due to its demonstrated activity against the virus causing Middle Eastern Respiratory Syndrome (MERS).
Zuranolone
go.drugbank.com/drugs/DB15490ApprovedInvestigationalUnlike other more common GABA<sub>A</sub> positive allosteric modulators on the market like benzodiazepines, zuranolone can modulate both synaptic and extrasynaptic GABA<sub>A</sub> conductance due to
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesGatifloxacin
go.drugbank.com/drugs/DB01044ApprovedInvestigationalWithdrawnThe FDA withdrew its approval for the use of non-ophthalmic drug products containing gatifloxacin due to the high prevalence of gatifloxacin-associated dysglycemia adverse event reports and the high incidence
Mixtures: GATIPHARM - D® (GATIFLOXACINA 0.3% + DEXAMETASONA 0.1% SOLUCIÓN OFTÁLMICA ESTERIL), GATIPHARM - D® (GATIFLOXACINA 0.3% + DEXAMETASONA 0.1% SOLUCIÓN OFTÁLMICA ESTERIL)Categories: P-glycoprotein substrates, Cytochrome P-450 CYP1A2 Inhibitors